Prostate Cancer

Daniel Allan Hamstra, MD, PhD, FASTRO, FASCO, discusses the importance of rectal spacers in reducing side effects and improving quality-of-life during radiation therapy for prostate cancer.

“It was interesting to find that when Black and White men were provided equal access to the same therapies, given at the same dosage and monitored in the same setting, disparities in outcomes were eliminated," says Jun Gong, MD.

"We're pleased to report that there was a strong prognostic signal we found with the overall cohort," says Charles Parker, MD.

The FDA’s Fast Track designation is designed to expedite the review and development of novel treatments that will fill an unmet medical need.

Patients were nearly twice as likely to develop urinary symptoms and urinary frequency when their prostatic urethra was greater than 4.6 cm in length.

Benjamin H. Lowentritt, MD, FACS, provides clinical insights on the use of different formulations of abiraterone as treatment for patients with prostate cancer.

“Relugolix is the first approved ADT in Canada that can be administered orally, and once daily, offering a safe and effective option for advanced prostate cancer patients in the country," said Fred Saad, MD.

A brief review of the evolving realm of prostate cancer care centered on the significance of identifying high-risk cases and addressing the complexities of risk stratification and prognosis.

Overview of hurdles and advancements in utilizing advanced imaging techniques for prostate cancer diagnosis, including agent availability, scheduling, facility preferences, and reimbursement.

A discussion surrounding the changing landscape of early-stage prostate cancer screening and rise in metastatic disease cases, focusing on the importance of timely intervention and patient-focused care.

Insight into advancements in prostate cancer imaging using PSMA agents like gallium and F-18, their unique characteristics, and the considerations in choosing the right radiotracer for accurate detection.

The phase 3 EMBARK trial showed that enzalutamide plus leuprolide reduced the risk of metastasis or death by nearly 60% vs leuprolide alone in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Delve into the strategic process of selecting ideal partners in cancer care as key opinion leaders share insights on building trust, effective communication, and optimizing patient outcomes through collaborative decision making.

Explore how David Morris, MD, FACS, and Benjamin Garmezy, MD, join forces to enhance patient outcomes in advanced prostate cancer through their innovative and collaborative precision medicine strategies.

“Where we are with this, I think that our results do not support the theory that agonists have a higher cardiovascular risk than antagonists,” says E. David Crawford, MD.

Amir H. Lebastchi, MD, provides perspectives on the VIOLETTE study and underscores the importance of future head-to-head trials to gain a deeper understanding of various treatment approaches.

"Hopefully this law will allow more patients with advanced prostate cancer to gain access to these medications, and to take it without substantially changing the quality of their life when it comes to financial consequences," says Benjamin Pockros, MD.

"Hopefully this gives patients and providers information that they can use to inform and set reasonable expectations of what patient's lives will look like after treatment," says Samuel L. Washington III, MD, MAS.

Explore the transformative journey of prostate cancer imaging techniques, from conventional methods to cutting-edge PET scans like F-18 PSMA, and how FDA approvals have shaped their adoption.

Join David Albala, MD, as he explores the use of advanced imaging techniques in prostate cancer diagnosis and management, highlighting PSMA-PET scans and their pivotal role in modern prostate cancer care.

“The ClarityDX Prostate test will reduce the number of unnecessary prostate biopsies, which are invasive, uncomfortable, and carry some risk,” says John D. Lewis, PhD.

"It's really a monumental change for patients, and it is a massive win for our health care system," says Benjamin Pockros, MD.

Dr. Amir H. Lebastchi elaborates on his approach to integrating MRI and ultrasound fusion-based technology for guiding treatment selection and tailoring therapy for patients with prostate cancer.

Amir H. Lebastchi, MD, outlines his general strategy for active surveillance in prostate cancer patients, emphasizing the role of MRI and fusion-guided prostate biopsy.

Preliminary findings from the study showed a decrease in PSA levels across all doses of PDS0301 assessed.

The phase 2 study explored the investigational agent BXCL701 in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer.

“I think this study gives us actual numbers, so we can have a sense of how much time people will take off over time,” says Samuel L. Washington, MD, MAS.

"A lot of patients with prostate cancer are going to receive one of these agents," says Tanya B. Dorff, MD.